Register entry
CMP DEVELOPMENT LLC
- Registered sites
- 0
- Drug products
- 0
- Live patents
- 33
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
33Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ATORVALIQ | ATORVASTATIN CALCIUM | Jun 2037 |
| CAROSPIR | SPIRONOLACTONE | Oct 2036 |
| LIQREV | SILDENAFIL CITRATE | Dec 2038 |
| NORLIQVA | AMLODIPINE BESYLATE | Feb 2041 |
| POTASSIUM PHOSPHATES | POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC | Apr 2039 |
| QLONILIK | CLONIDINE HYDROCHLORIDE | Aug 2045 |
| TADLIQ | TADALAFIL | Dec 2038 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.